Seres Therapeutics (NASDAQ:MCRB) : The money flow analysis of Seres Therapeutics (NASDAQ:MCRB) indicates a $0.03 million of outflow was on downticks, whereas, the investors on Wednesday gobbled up stocks worth $0.14 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 4.32 and so was the total money flow at $0.11 million. The bulls lapped up $0.01 million worth of block trades on upticks. The money flow was $0.01 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Seres Therapeutics (NASDAQ:MCRB), pushing it down by -0.03% for the day. The stock slid $0.01 and traded at $29.42 during the day. Nonetheless, the stock is 3.99% over the previous weeks close.
In an insider trading activity, Pomerantz Roger, director officer (President and CEO) of Seres Therapeutics, Inc., unloaded 74,049 shares at an average price of $32.39 on June 2, 2016. The total amount of the transaction was worth $2,398,447, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 41.9% of Seres Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -26.57% . Institutional Investors own 78.31% of Seres Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -43.04%.
Seres Therapeutics (NASDAQ:MCRB): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $29.55 and $29.15 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $29.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $29.84, notching a gain of 1.39% for the day. The total traded volume was 278,139 . The stock had closed at $29.43 on the previous day.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. Its SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.